newsfilter
← Latest News
GlobeNewswire·

Xenon Reports Q3 2026 Financial Results and Provides Business Update

New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies and